drugset
drugset / Trial / NCT01214603

A Study in Participants With Acute Leukemia

NCT01214603 ↗

Phase 2 Completed 20 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

This study is a multicenter, non-randomized, open-label, Phase 2 study of intravenous LY2090314 in participants with acute leukemia.

Timeline

Start
2010-11
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2090314 Small molecule 40 mg Intravenous

Indications

leukemia